BREAKING
Importance
45
Trust
71
Urgency
95
DEAL
HYTN plans separate BPC-157 drug company, targets $1M raise - Stock Titan
HYTN is starting a new company focused on BPC-157, a peptide drug candidate, and plans to raise $1 million to fund it. The move splits BPC-157 development into its own separate business unit.
Analysis
HYTN is spinning out its BPC-157 peptide work into a new company. The small $1M raise shows this is early-stage and far from a real drug.
- HYTN plans to spin out BPC-157 into a separate drug company
- The new entity is targeting a $1 million raise
Peptide Therapy Research1mo
Read